RxDoctor Payments Data

Derick Adams, DO

Endocrinology, Diabetes & Metabolism · Lexington, KYNPI 1558653162

Payments from drug & device makers

$2,014in general payments, 2019–2025

Across 104 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$267
  • AbbVie$217
  • Novo Nordisk$165
  • Averitas Pharma Inc.$156
  • Medtronic$129
  • Amgen$102
  • plus $977 from 21 others

What the payments were for

  • Food & beverage$1,90695%
  • Education$1095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,014 in reported general payments places this provider in the 25th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

See all endocrinology, diabetes & metabolism providers in Kentucky

Medicare billing

Part B allowed, 2024
$74,140
Medicare patients
347
Services billed
957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide286$348,121
TrulicityDulaglutide88$129,677
Tresiba Flextouch U-200Insulin Degludec75$116,165
JardianceEmpagliflozin83$99,202
MounjaroTirzepatide62$78,068
Tresiba Flextouch U-100Insulin Degludec84$75,583
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$70,100
JanuviaSitagliptin Phosphate51$59,517
Bydureon BciseExenatide Microspheres29$44,885
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$41,019
FarxigaDapagliflozin Propanediol43$40,972
Soliqua 100-33Insulin Glargine/Lixisenatide28$38,223
RybelsusSemaglutide29$38,117
Novolog FlexpenInsulin Aspart56$24,968
Fiasp FlextouchInsulin Aspart (Niacinamide)25$24,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$165$386,238315 claims
AstraZenecaFarxiga$36$40,97243 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$52$38,22328 claims
AbbVieSynthroid$217$12,543156 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$71$4,662467 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

Other endocrinology, diabetes & metabolism in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →